Welcome to MOLOGEN AG
Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.
We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.
Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need.
3 Questions to Dr. Söhngen
DR. MARIOLA SÖHNGEN CEO MOLOGEN AG
The biotech company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present pre-clinical data on its EnanDIM® technology, a new family of TLR9 agonists and so-called Immune Surveillance Reactivators (ISR), at the 19th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, U.S. (4-7... [more]
MOLOGEN AG announces that the United States Patent and Trademark Office (PTO) has declared that it will grant a patent (Notice of Allowance) for the combined use of the lead product, immunotherapy MGN1703, with a chemotherapeutic agent. [more]